5
Benzyl
4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-2H-1,2-
13C NMR (150 MHz, CDCl3) δ 155.0, 155.0, 137.2, 136.6,
ACCEPTED MANUSCRIPT
oxazine-2-carboxylate (10): According to the general procedure,
oxazine products 10 and 10a were isolated as a mixture (30 mg,
88%, 4:1). H NMR (600 MHz, CDCl3) δ 7.61 (d, J = 8.0 Hz,
134.6, 133.2, 128.7, 128.6, 128.0, 124.8, 124.8, 120.1, 118.5,
81.8, 81.8, 69.3, 68.2, 46.4, 45.2, 28.3, 28.3, 27.6; IR (thin film)
3058, 2978, 2849, 1702, 1496, 1367, 1235, 1164, 1099 cm-1; MS
1
2H), 7.45 (d, J = 8.0 Hz, 2H), 7.42 – 7.30 (m, 5H), 6.30 – 6.26
(m, 1H), 5.25 (s, 2H), 4.64 – 4.60 (m, 2H), 4.54 – 4.50 (m, 2H);
Mixture 13C NMR (150 MHz, CDCl3) δ 155.5, 155.5, 140.3,
139.9, 135.8, 133.8, 132.1, 130.1 (q, J = 32.7 Hz), 128.6, 128.4,
128.2, 128.2, 125.6 (q, J = 3.7 Hz), 125.1, 123.9 (q, J = 272.2
Hz), 122.2, 120.5, 69.6, 68.6, 68.0, 68.0, 46.1, 45.1; IR (thin
film) 3035, 2922, 2850, 1708, 1616, 1414, 1327, 1167, 1117,
1071 cm-1; HRMS (ESI) m/z 386.1095 (100%), 387.1143 (21%),
388.1161 (3%) (386.0980, 387.1014, 388.1047 calculated for
C19H16F3NO3Na [M+Na]+).
(ESI) m/z 284.13 (284.13 calculated for C15H19NO3Na [M+Na]+
).
4-(4-Methoxyphenyl)-3,6-dihydro-2H-1,2-oxazine-2-
carboxamide (19): According to the general procedure, oxazine
products 19 and 19a were isolated as a mixture (25 mg, 86%,
20:1). H NMR (600 MHz, CD3OD) δ 7.39 – 7.33 (m, 2H), 6.93
– 6.87 (m, 2H), 6.19 – 6.14 (m, 1H), 4.60 – 4.55 (m, 2H), 4.37 –
4.33 (m, 2H), 3.78 (s, 3H); 13C NMR (150 MHz, CD3OD) δ
161.8, 161.1, 133.8, 131.0, 127.0, 119.3, 115.1, 70.1, 55.7, 46.1;
IR (thin film) 3453, 3221, 2905, 1677, 1607, 1518, 1446, 1281,
1241, 1031 cm-1; HRMS (ESI) m/z 257.0966 (257.0902
calculated for C12H14N2O3Na [M+Na]+).
1
Benzyl 4-(2-methoxyphenyl)-3,6-dihydro-2H-1,2-oxazine-2-
carboxylate (11): According to the general procedure, oxazine
products 11 and 11a were isolated as a mixture (29 mg, 92%,
4-(3-Methoxyphenyl)-3,6-dihydro-2H-1,2-oxazine-2-
carboxamide (21): According to the general procedure, oxazine
products 21 and 21a were isolated as a mixture (24 mg, 82%,
4:1). H NMR (600 MHz, CD3OD) δ 7.25 (t, J = 8.0 Hz, 1H),
7.01 – 6.82 (m, 3H), 6.29 – 6.26 (m, 1H), 4.61 – 4.56 (m, 2H),
4.38 – 4.34 (m, 2H), 3.79 (s, 3H); 13C NMR (150 MHz, CD3OD)
δ 160.3, 160.0, 138.6, 132.9, 129.3, 120.1, 116.8, 113.1, 110.2,
68.6, 54.2, 44.7; IR (thin film) 3469, 3331, 2924, 1676, 1580,
1430, 1288, 1210, 1050 cm-1; HRMS (ESI) m/z 257.0966
(257.0902 calculated for C12H14N2O3Na [M+Na]+).
1
4:1). H NMR (600 MHz, CDCl3) δ 7.43 – 7.25 (m, 6H), 7.19 –
7.14 (m, 1H), 6.96 – 6.84 (m, 2H), 5.95 – 5.91 (m, 1H), 5.23 (s,
2H), 4.63 – 4.58 (m, 2H), 4.55 – 4.51 (m, 2H), 3.77 (s, 3H); 13C
NMR (150 MHz, CDCl3) δ 156.9, 155.6, 136.1, 133.8, 129.5,
129.4, 128.6, 128.3, 128.2, 121.9, 120.9, 110.9, 77.2, 68.8, 67.7,
55.4, 47.5; IR (thin film) 3064, 3033, 2943, 2838, 1727, 1706,
1597, 1490, 1455, 1343, 1215, 1094 cm-1; HRMS (ESI) m/z
348.1326 (348.1212 calculated for C19H19NO4Na [M+Na]+).
1
Benzyl 4-methyl-3,6-dihydro-2H-1,2-oxazine-2-carboxylate
(12) and benzyl hydroxy(2-methylenebut-3-en-1-yl)carbamate
(S-6): According to the general procedure, oxazine products 12
and 12a were isolated as a mixture (62 mg, 48%, 2:1) separate
N-Benzyl-4-(3-methoxyphenyl)-3,6-dihydro-2H-1,2-oxazine-
2-carboxamide (22): According to the general procedure,
oxazine products 22 and 22a were isolated as a mixture (31 mg,
1
77%, 7:1). H NMR (600 MHz, CDCl3) δ 7.38 – 7.23 (m, 6H),
1
from carbamate product S-6 (49 mg, 38%). (12): H NMR (600
7.03 – 6.82 (m, 3H), 6.19 – 6.15 (m, 1H), 4.59 – 4.56 (m, 2H),
4.49 (d, J = 5.8 Hz, 2H), 4.47 – 4.44 (m, 2H), 3.81 (s, 3H); 13C
NMR (150 MHz, CDCl3) δ 159.8, 158.6, 138.7, 138.7, 133.8,
129.6, 128.7, 127.7, 127.4, 119.9, 117.5, 113.5, 110.8, 69.3, 55.3,
46.3, 44.0; IR (thin film) 3341, 3033, 2933, 2837, 1670, 1523,
1431, 1288, 1209, 1049 cm-1; HRMS (ESI) m/z 347.1475
(347.1372 calculated for C19H20N2O3Na [M+Na]+).
MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 5.54 – 5.47 (m, 1H), 5.20 (s,
2H), 4.40 – 4.34 (m, 2H), 4.02 – 3.98 (m, 2H), 1.72 (s, 3H);
(12a): 1H NMR (600 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 5.54 –
5.47 (m, 1H), 5.20 (s, 2H), 4.28 – 4.24 (m, 2H), 4.12 – 4.06 (m,
2H), 1.64 (s, 3H); Mixture: 13C NMR (150 MHz, CDCl3) δ 155.6,
155.5, 136.0, 136.0, 131.5, 130.1, 128.5, 128.5, 128.2, 128.1,
128.1, 118.0, 116.2, 71.6, 68.5, 67.7, 67.7, 48.5, 44.7, 19.7, 18.3.
4-(3-Methoxyphenyl)-N-phenyl-3,6-dihydro-2H-1,2-oxazine-
2-carboxamide (23): According to the general procedure, oxazine
products 23 and 23a were isolated as a mixture (25 mg, 64%,
4:1). 1H NMR (600 MHz, CDCl3) δ 7.73 (s, 1H), 7.55 – 7.26 (m,
5H), 7.11 – 6.81 (m, 4H), 6.22 – 6.19 (m, 1H), 4.72 – 4.67 (m,
2H), 4.53 – 4.49 (m, 2H), 3.82 (s, 3H); 13C NMR (150 MHz,
CDCl3) δ 160.0, 155.7, 138.7, 138.0, 133.9, 129.9, 129.8, 129.2,
123.7, 119.8, 119.5, 117.7, 113.8, 111.0, 77.2, 69.9, 55.5, 45.9;
IR (thin film) 3321, 3063, 2920, 2837, 1675, 1531, 1446, 1288,
1208, 1050 cm-1; HRMS (ESI) m/z 333.1364 (333.1215
calculated for C18H18N2O3Na [M+Na]+).
Benzyl 4-(1-((tert-butyldimethylsilyl)oxy)ethyl)-3,6-dihydro-
2H-1,2-oxazine-2-carboxylate (14): According to the general
procedure, oxazine products 14 and 14a were isolated as a
1
mixture (95 mg, 77%, 1:13). H NMR (600 MHz, CDCl3) δ 7.39
– 7.27 (m, 5H), 5.67 – 5.62 (m, 1H), 5.20 (s, 2H), 4.46 – 4.39 (m,
2H), 4.25 (q, J = 6.6 Hz, 1H), 4.14 – 4.10 (m, 2H), 1.19 (d, J =
6.5 Hz, 3H), 0.86 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); 13C NMR
(150 MHz, CDCl3) δ 155.5, 139.8, 136.0, 128.5, 128.2, 128.1,
115.0, 69.3, 68.4, 67.7, 44.6, 25.7, 23.2, 18.1, -4.8, -4.9; IR (thin
film) 3066, 2955, 2856, 1712, 1343, 1214, 1088 cm-1; MS (ESI)
m/z 400.21 (400.19 calculated for C20H31NO4SiNa [M+Na]+).
4-(4-(Trifluoromethyl)phenyl)-3,6-dihydro-2H-1,2-oxazine-2-
carboxamide (24): According to the general procedure, oxazine
products 24 and 24a were isolated as a mixture (109 mg, 72%,
15:1). 1H NMR (600 MHz, CD3OD) δ 7.67 (d, J = 8.5 Hz, 2H),
7.64 (d, J = 8.5 Hz, 2H), 6.50 – 6.46 (m, 1H), 4.67 – 4.62 (m,
2H), 4.46 – 4.41 (m, 2H); 13C NMR (150 MHz, CD3OD) δ
160.3, 140.9, 131.9, 129.45 (q, J = 32.3 Hz), 125.20 (q, J = 3.8
Hz), 125.0, 122.6, 121.0, 68.6, 44.5; IR (thin film) 3420, 3192,
2959, 2846, 1638, 1592, 1326, 1171, 1128, 1070 cm-1; MS (ESI)
m/z 295.06 (100%), 296.07 (25%), 297.07 (6%) (295.07, 296.07,
297.08 calculated for C12H11F3N2O2Na [M+Na]+).
2,2,2-Trichloroethyl 4-phenyl-3,6-dihydro-2H-1,2-oxazine-2-
carboxylate (17): According to the general procedure, oxazine
products 17 and 17a were isolated as a mixture (94 mg, 81%,
1
8:1). H NMR (600 MHz, CDCl3) δ 7.38 – 7.28 (m, 5H), 6.22 –
6.18 (m, 1H), 4.84 (s, 2H), 4.69 – 4.65 (m, 2H), 4.61 – 4.57 (m,
2H); 13C NMR (150 MHz, CDCl3) δ 153.6, 136.7, 132.8, 128.8,
128.3, 124.9, 119.7, 95.1, 75.1, 68.9, 46.2; IR (thin film) 3059,
2955, 2851, 1745, 1720, 1496, 1436, 1347, 1229, 1114 cm-1;. MS
(ESI) m/z 357.99 (100%), 359.99 (95%), 361.98 (33%) (357.98,
359.98, 361.97 calculated for C13H12Cl3NO3Na [M+Na]+).
tert-Butyl 4-phenyl-3,6-dihydro-2H-1,2-oxazine-2-carboxylate
N-Benzyl-4-(4-(trifluoromethyl)phenyl)-3,6-dihydro-2H-
1,2-oxazine-2-carboxamide (25): According to the general
procedure, oxazine products 25 and 25a were isolated as a
mixture (118 mg, 58%, 4:1). 1H NMR (600 MHz, CDCl3) δ 7.61
(d, J = 8.2 Hz, 2H), 7.49 (d, J = 8.1 Hz, 2H), 7.40 – 7.25 (m, 5H),
(18): According to the general procedure, oxazine products 18
1
and 18a were isolated as a mixture (70 mg, 77%, 3:1). H NMR
(600 MHz, CDCl3) δ 7.38 – 7.23 (m, 5H), 6.19 – 6.15 (m, 1H),
4.60 – 4.55 (m, 2H), 4.46 – 4.42 (m, 2H), 1.51 (s, 9H); Mixture